Causal Associations Between Immune Cell Phenotypes and Varicose Veins: A Mendelian Randomization Analysis
Sunqi Nian,
No information about this author
Kui Wang,
No information about this author
Jiawei Wang
No information about this author
et al.
Annals of Vascular Surgery,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 1, 2025
Language: Английский
Circulating cell-free DNA methylation analysis of pancreatic cancer patients for early noninvasive diagnosis
Wenzhe Hu,
No information about this author
Xudong Zhao,
No information about this author
Nan Luo
No information about this author
et al.
Frontiers in Oncology,
Journal Year:
2025,
Volume and Issue:
15
Published: March 10, 2025
Background
Aberrant
hypermethylation
of
genomic
DNA
CpG
islands
(CGIs)
is
frequently
observed
in
human
pancreatic
cancer
(PAC).
A
plasma
cell-free
(cfDNA)
methylation
analysis
method
can
be
utilized
for
the
early
and
noninvasive
detection
PAC.
This
study
also
aimed
to
differentiate
PAC
from
other
types.
Methods
We
employed
methylated
tandem
amplification
sequencing
(MCTA-Seq)
method,
which
targets
approximately
one-third
CGIs,
on
samples
patients
(n
=
50)
healthy
controls
52),
as
well
cancerous
adjacent
noncancerous
tissue
66).
The
method’s
efficacy
detecting
distinguishing
it
hepatocellular
carcinoma
(HCC),
colorectal
(CRC),
gastric
(GC)
was
evaluated.
Additionally,
a
score
typing
system
established.
Results
identified
total
120
cfDNA
biomarkers,
including
IRX4
,
KCNS2
RIMS4
blood.
panel
comprising
these
biomarkers
achieved
sensitivity
97%
86%
discovery
validation
cohorts,
respectively,
with
specificity
100%
both
cohorts.
scoring
systems
were
clinically
applicable.
Furthermore,
we
hundreds
differentially
between
HCC,
CRC,
GC.
Certain
combinations
markers
used
highly
specific
(approximately
100%)
algorithm
GC
Conclusions
Our
PAC,
offering
novel
approach
early,
diagnosis
Language: Английский
Metabolic reprogramming shapes the immune microenvironment in pancreatic adenocarcinoma: prognostic implications and therapeutic targets
Weihua Song,
No information about this author
Yabin Yu,
No information about this author
Shuai Wang
No information about this author
et al.
Frontiers in Immunology,
Journal Year:
2025,
Volume and Issue:
16
Published: March 21, 2025
Introduction
Pancreatic
adenocarcinoma
(PAAD)
is
characterized
by
a
profoundly
immunosuppressive
tumor
microenvironment
(TME)
that
limits
the
efficacy
of
immunotherapy.
Emerging
evidence
suggests
tumor-specific
metabolic
reprogramming
may
drive
disease
progression
and
shape
immune
landscape
in
PAAD.
Methods
We
integrated
multi-omics
data
from
TCGA,
GEO,
ICGC
to
identify
key
metabolism-related
genes
(MRGs)
influence
cell
infiltration,
progression,
patient
survival.
Based
on
nine
pivotal
MRGs
(including
ANLN,
PKMYT1,
HMGA1),
we
developed
validated
novel
metabolic-prognostic
index
(MPI).
Functional
enrichment
analyses
were
conducted
elucidate
pathways
associated
with
different
MPI
risk
groups.
In
vitro
experiments
drug
sensitivity
performed
confirm
oncogenic
role
selected
explore
their
therapeutic
implications.
Results
The
effectively
stratified
patients
into
high-
low-risk
High-MPI
scores
correlated
poor
overall
survival,
elevated
mutation
burden
(TMB),
an
TME,
evidenced
reduced
CD8⁺
T-cell
infiltration
increased
expression
checkpoints
(PD-L1,
TGF-β).
revealed
glycolysis
folate
biosynthesis
as
dominant
high-MPI
groups,
whereas
fatty
acid
metabolism
prevailed
low-MPI
Experimental
validation
underscored
ANLN
promoting
epithelial-mesenchymal
transition
(EMT)
evasion
via
NF-κB
signaling.
knockdown
significantly
glycolytic
activity,
migration,
evasion.
Drug
indicated
resistance
gemcitabine
but
afatinib
patients.
Although
TIDE
analysis
predicted
checkpoint
inhibitor
(ICI)
tumors,
subset
showed
favorable
responses
anti-PD-L1
therapy.
Discussion
These
findings
provide
comprehensive
framework
for
understanding
how
shapes
PAAD’s
TME
affects
treatment
outcomes.
By
accurately
stratifying
patients,
serves
promising
tool
guide
decisions,
including
targeted
therapy
selection
immunotherapy
prediction,
ultimately
offering
potential
more
personalized
management
Language: Английский
Immune cells mediate the effect of plasma lipidomes on IgA nephropathy: a Mendelian randomization study
Quanxin Li,
No information about this author
Y. Eugene Chen,
No information about this author
Yueqin Zhu
No information about this author
et al.
Renal Failure,
Journal Year:
2025,
Volume and Issue:
47(1)
Published: May 6, 2025
IgA
nephropathy
(IgAN)
is
a
leading
cause
of
chronic
kidney
disease,
often
associated
with
dyslipidemia
and
immune
dysfunction.
This
study
employs
Mendelian
randomization
(MR)
to
investigate
the
causal
relationship
between
plasma
lipidomes
IgAN,
focus
on
potential
mediating
role
cells.
We
analyzed
179
genetically
predicted
IgAN
gene
using
two-sample
(TSMR)
multivariable
MR
based
summary-level
data
from
genome-wide
association
study,
results
were
validated
by
liquid
chromatography-mass
spectrometry.
Furthermore,
we
quantified
proportional
effect
cell-mediated
TSMR.
identified
significant
relationships
3
risk
examining
lipidome
traits
as
exposures.
To
whether
impact
lipid
groups
specific,
performed
TSMR
analyses
exposure
factors
4
nephritides
outcomes.
Specifically,
only
phosphatidylinositol
(18:1_20:4)
was
found
have
negative
incidence
(IVW
method,
p
=
0.01,
OR
0.71,
95%
CI
0.55
-
0.92).
Our
further
analysis
focused
8
cells
IgAN.
2
cell
phenotypes
that
may
contribute
(18:1_20:4)-mediated
careful
screening.
findings
provide
robust
genetic
evidence
supporting
link
acting
mediators.
Phosphatidylinositol
emerges
promising
biomarker
for
stratification,
early
detection,
therapeutic
intervention.
Modulating
its
levels
offer
novel
avenues
management.
Language: Английский